search
Back to results

CivaDerm(TM) Surface Therapy Pilot Study

Primary Purpose

Basal Cell Carcinoma, Squamous Cell Carcinoma of the Skin

Status
Not yet recruiting
Phase
Early Phase 1
Locations
Study Type
Interventional
Intervention
CivaDerm
Sponsored by
CivaTech Oncology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Basal Cell Carcinoma focused on measuring radiation, brachytherapy, skin cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • subject signed informed consent
  • Confirmed superficial or nodular basal cell or squamous cell carcinoma
  • Biopsy proven on chest, stomach, back, arms, legs, feet (trunk and extremities)
  • >5 mm of residual tumor
  • tumors < 3 cm
  • Capable of complying with Patient Release Instructions

Exclusion Criteria:

  • Is unable or unwilling to comply with the protocol requirements
  • Pregnant or breast feeding
  • Metastases

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Treatment

    Arm Description

    Radioactive bandage applied to surface of the body worn for approximately one week.

    Outcomes

    Primary Outcome Measures

    skin toxicity events
    grade 3+ events

    Secondary Outcome Measures

    dose delivered to target
    calculated radiation dose

    Full Information

    First Posted
    July 16, 2020
    Last Updated
    July 18, 2022
    Sponsor
    CivaTech Oncology
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04480645
    Brief Title
    CivaDerm(TM) Surface Therapy Pilot Study
    Official Title
    CivaDerm(TM) Surface Therapy Pilot Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 1, 2022 (Anticipated)
    Primary Completion Date
    February 1, 2023 (Anticipated)
    Study Completion Date
    April 30, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    CivaTech Oncology

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is a pilot study to determine the usefulness of new brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit basal cell and squamous cell carcinoma patients by providing conformal radiation therapy to the surface of the skin.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Basal Cell Carcinoma, Squamous Cell Carcinoma of the Skin
    Keywords
    radiation, brachytherapy, skin cancer

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Early Phase 1
    Interventional Study Model
    Single Group Assignment
    Model Description
    Single arm pilot study
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    10 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Treatment
    Arm Type
    Experimental
    Arm Description
    Radioactive bandage applied to surface of the body worn for approximately one week.
    Intervention Type
    Device
    Intervention Name(s)
    CivaDerm
    Intervention Description
    radioactive bandage
    Primary Outcome Measure Information:
    Title
    skin toxicity events
    Description
    grade 3+ events
    Time Frame
    within 2 months of treatment
    Secondary Outcome Measure Information:
    Title
    dose delivered to target
    Description
    calculated radiation dose
    Time Frame
    1 week

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: subject signed informed consent Confirmed superficial or nodular basal cell or squamous cell carcinoma Biopsy proven on chest, stomach, back, arms, legs, feet (trunk and extremities) >5 mm of residual tumor tumors < 3 cm Capable of complying with Patient Release Instructions Exclusion Criteria: Is unable or unwilling to comply with the protocol requirements Pregnant or breast feeding Metastases
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Kristy Perez, PhD
    Phone
    9193145515
    Email
    kperez@civatechoncology.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Carra Castagnero
    Phone
    9193145515
    Email
    clinical@civatechoncology.com

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    CivaDerm(TM) Surface Therapy Pilot Study

    We'll reach out to this number within 24 hrs